Boosting sales of Egrifta VISCERAL FAT REDUCTION WITH TESAMORELIN ASSOCIATED WITH METABOLIC SYNDROME REVERSAL
VISCERAL FAT REDUCTION WITH TESAMORELIN ASSOCIATED WITH METABOLIC SYNDROME REVERSAL
"This is consistent with previous data indicating that visceral fat reduction is associated with improvements in metabolic parameters of PWH, and thus supports the use of tesamorelin in PWH with central adiposity to improve metabolic profiles."
Of some reason some months later this presentation is showing on line!
One has to assume it is much more alarming warnings among patients in risk of CVD, stroke, diabetes than lipodystrophy because most patients still are not fully aware of lipodystrophy and its consequences but just about anyone knows what heart attacks are. I certainly hope these therapeutic effects of Tesamorelin are pitched well to both patients and their doctors resulting in better uptake and retention of the drug.